Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

被引:6
|
作者
Zhang, Qiongwen [1 ,2 ]
He, Ping [3 ]
Tian, Tinglun [3 ]
Yan, Xi [3 ]
Huang, Juan [4 ]
Zhang, Zhang [5 ]
Zheng, Hong [3 ,6 ]
Zhong, Xiaorong [3 ,6 ]
Luo, Ting [3 ,6 ]
机构
[1] Sichuan Univ, Canc Ctr, West China Hosp, Dept Radiat Oncol,Dept Head & Neck Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Breast Dis Ctr, Canc Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Innovat Ctr Biotherapy, Multi Lab Breast Dis,State Key Lab Biotherapy,Natl, Chengdu, Peoples R China
关键词
HER2-positive breast cancer; real-world studies; brain metastase; pyrotinib; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITOR; BRAIN METASTASES; CHEMOTHERAPY; TRASTUZUMAB; CISPLATIN;
D O I
10.3389/fphar.2023.1100556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metastatic breast cancer, have been rarely reported. Here, we evaluated the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive metastatic breast cancer (MBC).Methods: This was a prospective, real-world, observational cohort study. Through the Breast Cancer Information Management System, HER-2 positive MBC patients treated with pyrotinib between 2017/06 and 2020/09 were included. Provider-reported objective response rate, progression-free survival (PFS), and overall survival (OS) were considered in the assessment of treatment outcomes. Tumor responses to pyrotinib treatment were calculated using RECIST 1.1. Adverse events were evaluated using clinical records.Results: The trial involved 113 individuals who were receiving pyrotinib treatment, with an average age of 51 years. Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively, while progressive disease was recorded in 20 (17.7%) patients. After a median follow-up of 17.2 months, the median PFS was 14.1. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), and palmar-plantar erythrodysesthesia (26.6%). Among the patients with brain metastases, the median PFS and OS were 15.2 and 19.8 months, respectively. In addition, pyrotinib has similar efficacy in various subtypes of HER2-positive MBC patients, as shown by the lack of a significant difference of PFS and OS among pyrotinib-treated patients with or without brain metastases, or patients using pyrotinib as first-line, second-line, third-line or beyond therapies.Conclusion: Our real-world results demonstrated equivalent clinical efficacy in HER-2 positive MBC patients compared to phase II and phase III clinical trials with pyrotinib, and promising outcomes in patients with brain metastases.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
    Li, Yiqun
    Tong, Zhongsheng
    Wu, Xinhong
    Ouyang, Quchang
    Cai, Li
    Li, Wei
    Yu, Zhiyong
    Han, Zhengxiang
    Wang, Xiaojia
    Li, Man
    Wang, Haibo
    Li, Li
    Yang, Jin
    Niu, Zhaofeng
    Wang, Qitang
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (10) : 1809 - 1818
  • [42] Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
    Lux, Michael P.
    Nabieva, Naiba
    Hartkopf, Andreas D.
    Huober, Jens
    Volz, Bernhard
    Taran, Florin-Andrei
    Overkamp, Friedrich
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Geberth, Matthias
    Abenhardt, Wolfgang
    Kurbacher, Christian
    Wuerstlein, Rachel
    Thomssen, Christoph
    Untch, Michael
    Fasching, Peter A.
    Janni, Wolfgang
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Schneeweiss, Andreas
    Brucker, Sara Y.
    CANCERS, 2019, 11 (01):
  • [43] Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
    Yang, D. Y.
    Sun, T.
    Chen, Z-H.
    Ouyang, Q.
    Li, K.
    Yan, M.
    Lv, Z.
    Li, Z.
    Man, L.
    Luo, X.
    Dong, Y.
    Jing, M.
    Wang, Y.
    Guo, X.
    Xu, J.
    Li, X.
    Jiang, C.
    Jiang, Y. E. L.
    Cao, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S377 - S377
  • [44] Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
    Sang, Die
    Su, Yanfang
    Zhang, Yurong
    Guan, Yanfeng
    Fan, Shanmin
    Zhang, Jintao
    Zheng, Lijun
    Wang, Yanling
    Guo, Ying
    Lei, Zixuan
    Li, Man
    Yuan, Peng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [45] A real-world study on prevalence of and outcomes related to brain metastases among patients with HER2-positive metastatic breast cancer (mBC)
    Collins, J.
    Varghese, D.
    Miranda, M.
    Nordstrom, B.
    Murphy, B.
    Harland, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S213 - S213
  • [46] The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
    Ouyang, D. J.
    Chen, Q. T.
    Anwar, M.
    Xie, N.
    Ouyang, Q. C.
    Fan, P. Z.
    Qian, L. Y.
    Chen, G. N.
    Zhou, E. X.
    Guo, L.
    Gu, X. W.
    Ding, B. N.
    Yang, X. H.
    Liu, L. P.
    Deng, C.
    Xiao, Z.
    Li, J.
    Wang, Y. Q.
    Zeng, S.
    Wang, Shouman
    Yi, Wenjun
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [47] Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study
    Wu, Qichao
    Wang, Kuanyu
    Sun, Shibin
    Ding, Xiaosheng
    Hua, Yichun
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer
    Batra, Atul
    Rigo, Rodrigo
    Hannouf, Malek B.
    Cheung, Winson Y.
    CLINICAL COLORECTAL CANCER, 2021, 20 (02) : E75 - E81
  • [49] Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
    Sanglier, Thibaut
    Shim, Jinjoo
    Lamarre, Neil
    Pena-Murillo, Claudia
    Antao, Vincent
    Montemurro, Filippo
    BREAST, 2023, 69 : 441 - 450
  • [50] Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy A Multicenter Retrospective Analysis
    Liu, Jing
    Sun, Xianglu
    Du, Qianyu
    Yao, Jinghao
    Dai, Mengfen
    Cheng, Qianqian
    Xu, Han
    Li, Yawei
    Liu, Xiuli
    Zhang, Mingliang
    Zhou, Yongchun
    Yang, Yan
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 491 - 504